Omnicell (OMCL) Net Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Omnicell (OMCL) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | -9.45% |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | -16.59% |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | -0.80% |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 60.16% |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | -85.83% |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 43.26% |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | 1.60% |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | -26.30% |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | -339.28% |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn | -19.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19.31% |
| Mar 31, 2026 | 139.35% |
| Dec 31, 2025 | -28.50% |
| Sep 30, 2025 | -153.76% |
| Jun 30, 2025 | 41.98% |
| Mar 31, 2025 | 30.31% |
| Dec 31, 2024 | -14.98% |
| Sep 30, 2024 | 28.02% |
| Jun 30, 2024 | -24.10% |
| Mar 31, 2024 | -6.12% |
| Dec 31, 2023 | 31.62% |
| Sep 30, 2023 | -54.82% |
| Jun 30, 2023 | 27.84% |
| Mar 31, 2023 | 28.75% |
| Dec 31, 2022 | 103.72% |
| Sep 30, 2022 | -34.12% |
| Jun 30, 2022 | -54.39% |
| Mar 31, 2022 | -107.60% |
| Dec 31, 2021 | -93.83% |
| Sep 30, 2021 | -396.26% |